Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $11.9 million.

  • Foghorn Therapeutics' Share-based Compensation fell 9.44% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $11.9 million for FY2024, which is 26.52% down from last year.
  • As of FY2024, Foghorn Therapeutics' Share-based Compensation stood at $11.9 million, which was down 26.52% from $16.2 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Share-based Compensation high stood at $16.2 million for FY2023, and its period low was $3.0 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $14.3 million (2022), whereas its average is $14.1 million.
  • In the last 5 years, Foghorn Therapeutics' Share-based Compensation spiked by 183.15% in 2021 and then declined by 26.52% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Share-based Compensation (Yearly) stood at $3.0 million in 2020, then soared by 183.15% to $8.4 million in 2021, then spiked by 70.99% to $14.3 million in 2022, then increased by 12.90% to $16.2 million in 2023, then declined by 26.52% to $11.9 million in 2024.